PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
89.98%
Positive net income growth while Drug Manufacturers - Specialty & Generic median is negative at -4.74%. Peter Lynch would view it as a strong advantage vs. struggling peers.
-14.14%
D&A shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a short-term earnings benefit if capacity is sufficient.
85.44%
Deferred tax growth of 85.44% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would see a difference that might matter for future cash flow if significant.
2.07%
SBC growth of 2.07% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or staff additions causing more equity grants.
241.46%
Working capital of 241.46% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would check if expansions or cost inefficiencies cause that difference.
-222.19%
AR shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see an advantage in working capital if sales do not drop.
93.32%
Inventory growth of 93.32% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question if expansions or new product lines require extra stock.
1141.22%
AP growth of 1141.22% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or credit policies affecting the difference.
304.96%
Growth of 304.96% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.
-92.82%
Other non-cash items dropping yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a short-term advantage if real fundamentals remain intact.
334.00%
CFO growth of 334.00% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would see a small edge that may compound with consistent execution.
-1347.61%
CapEx declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would note a short-term FCF advantage if revenue is stable.
137.44%
Acquisition growth of 137.44% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or partial deals fueling that difference.
234.95%
Purchases growth of 234.95% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or new strategic positions driving the difference.
-100.00%
We liquidate less yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a firm-specific hold strategy unless missed gains exist.
14093.33%
Growth of 14093.33% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss questions intangible or special projects explaining that difference.
-65.16%
Reduced investing yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.
-2637.45%
Debt repayment yoy declines while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman fears increased leverage if expansions do not yield quick returns.
-100.00%
We reduce issuance yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see an advantage in preserving per-share value unless expansions are neglected.
100.00%
Buyback growth of 100.00% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or higher yoy CFO enabling that difference.